Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.65 |
| ▸ | GNPAT | O15228 | 1/20 | 0.58 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411666 | 0.95 | NAALAD2 (0.65) | NAALAD2CTRB1MMEBACE1ACE | |
| SCHEMBL30658570 | 0.93 | NAALAD2 (0.56) | NAALAD2GNPATMMP1MMP8MME | |
| SCHEMBL38657669 | 0.91 | BACE1 (0.59) | NAALAD2MMEBACE1 | |
| SCHEMBL29538789 | 0.89 | BACE1 (0.54) | NAALAD2BACE1 | |
| SCHEMBL29702065 | 0.89 | MME (0.61) | GNPATCTRB1MMEACECPA1 | |
| SCHEMBL30692726 | 0.88 | NAALAD2 (0.67) | NAALAD2GNPATMMP1MMP8FOLH1 | |
| SCHEMBL29892410 | 0.88 | NAALAD2 (0.67) | NAALAD2GNPATFOLH1HPGDBACE1 | |
| SCHEMBL30533128 | 0.88 | NAALAD2 (0.50) | NAALAD2GNPATCTRB1MMP1MMP8 | |
| SCHEMBL30193491 | 0.88 | NAALAD2 (0.60) | NAALAD2GNPATBACE1 | |
| SCHEMBL30799469 | 0.87 | MME (0.60) | GNPATCTRB1MMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376151-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376151-A1 | STAPLED PEPTIDES AND METHODS THEREOF | VIP, IAPP, GLP1R | NAALAD2 1140/4885GNPAT 4174/4885CTRB1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.